Phase
Condition
Dementia
Treatment
Cannabis Sativa Oil
Placebo
Clinical Study ID
Ages > 55 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients with severe dementia from different origins (Alzheimer's disease, vascular,mixed)
Clinical Dementia Rating ≥3
Persisting behavior problems (Neuropsychiatric Inventory [NPI] score > 10)notwithstanding optimal conventional treatment
SARS-CoV-2 recovered for two weeks, or SARS-CoV-2 fully vaccinated
Consent obtained from the representative in the medical field according to art 378Swiss Civil Code (SCC)
Exclusion
Exclusion Criteria:
Severe organ deficiency such as cardiac, pulmonary, hepatic, renal insufficiency, orunstable heart rhythm
Symptomatic orthostatic hypotension
Major changes or instability of psychotropic medication in the week preceding thestudy enrolment
Having taken THC and/or CBD in the 7 days before enrolment
Hemoglobin < 10 g/dl
Severe kidney failure defined by cockcroft calculation <30 ml/mn
Alanine aminotransferase and aspartate aminotransferase > 3x upper limit of normal
Any other medical conditions that would prevent participation in the whole studyprotocol.
Study Design
Study Description
Connect with a study center
FAHPA
Geneva, 1206
SwitzerlandSite Not Available


Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.